EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial methotrexate therapy fails.
BARCELONA, Spain — Patients with rheumatoid arthritis who have not responded to first-line methotrexate therapy should be started on a biologic or targeted synthetic disease-modifying antirheumatic drug , according to new recommendations by the European Alliance of Associations for Rheumatology .
These updated recommendations contain five overarching principles and nine recommendations — two fewer than those in the. Several of the recommendations remain unchanged, and a few were merged or modified to provide greater clarity. “The availability of an increasing number of good drugs and increasing evidence due to wonderful clinical trials made the task force in charge of these recommendations produce increasingly leaner recommendations,” said Josef S. Smolen, MD, of the Medical University of Vienna, Vienna, Austria, who presented them at theEULAR continues to recommend methotrexate and short-term glucocorticoids as the first treatment strategy for RA. However, if the treatment target is not reached with this first conventional synthetic DMARD approach, then the patient should be started on a b/tsDMARD.This update eliminates treatment based on stratification according to poor prognostic factors, such as the presence of autoantibodies or high disease activity. In the 2022 recommendations, patients without these factors could start another csDMARD, whereas those with these poor prognostic factors could start a b/tsDMARD. “The task force felt that the stratification was not necessary because if you fail methotrexate plus glucocorticoids, you already have a bad prognostic sign,” Smolen explained. Alexandre Sepriano, MD, PhD, an assistant professor of rheumatology at NOVA University Lisbon, Lisbon, Portugal, thought this change was the “most important modification” to these RA treatment guidelines and would have “significant implications for clinical practice.” He co-moderated the session where these updated recommendations were presented.“In some countries , patients previously had to fail two csDMARDs before being eligible for a biologic or JAK inhibitor,” added Kim Lauper, MD, PhD, of Geneva University Hospitals, Geneva, Switzerland, the other moderator of the session. “This new recommendation could help support policy changes that allow for earlier escalation, potentially helping more patients reach remission faster.” EULAR still recommends that b/tsDMARDs be combined with a csDMARD. In patients who cannot use a csDMARD as a co-medication, interleukin 6 inhibitors and JAK inhibitors “may have some advantages compared with other bDMARDs,” the recommendations state.EULAR advises that clinicians should evaluate cardiovascular and malignancy risk factors before prescribing a JAK inhibitor. While thefound that the risk for major cardiovascular events and cancer was more common with tofacitinib than with TNF inhibitors, patient registries have not shown these same patterns, Smolen said. More randomized controlled trials are therefore needed to understand what could be driving the risk, he added.“We’re awaiting more data, and we would love to see and understand the mechanisms that led to a higher incidence of malignancies and cardiovascular events ,” he said. Once a patient achieves sustained remission, they can taper to a lower DMARD dose; however, the new guidelines emphasize the importance of remaining on DMARDs and not stopping them entirely, Smolen said. “Now, we more clearly state that this task force, based on newer data, felt that continuation of DMARDs — whether traditional , biologic, or targeted synthetic DMARDs — is recommended, but dose reduction may be considered,” he continued. Smolen reported receiving grant support from AbbVie, AstraZeneca, Galapagos, and Lilly and honoraria from Abbott, AnaptysBio, Ananda, Celltrion, Immunovant, Janssen, Lilly, Novartis-Sandoz, R-Pharma, Roche-Chugai, and UCB. Sepriano reported receiving speaking and/or consulting fees from AbbVie, Novartis, UCB, and Lilly. Lauper reported receiving speaking and/or consulting fees and/or grants from AbbVie, Novartis, Eli Lilly, Galapagos, Alfasigma, and Pfizer.
Rheumatoid Arthritis (RA) Biologic Therapy Biologics Arthritis Joint Inflammation Disease-Modifying Antirheumatic Drugs Dmards DMARD Glucocorticosteroids Glucocorticoid Therapy Glucocorticoid Treatment Guidelines Clinical Guidelines Guidelines Grant Remission Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Clinical Research Clinical Trials
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CDC official who oversaw COVID vaccine recommendations resignsThe move comes after a week of mixed messages on COVID vaccine recommendations.
Read more »
UW doctor challenges RFK Jr.'s COVID vaccine recommendationsHeather Bosch is a multi-award winning journalist who returned to the Pacific Northwest after working as a CBS Network News Correspondent, based in New York City. Heather has covered stories including the Orlando Pulse Nightclub shooting, the Boston Marathon bombing and trial, and the devastating EF-5 tornado in Joplin.
Read more »
BFI Report Sets Out 9 Recommendations to Ensure “Ethical, Sustainable, Inclusive AI” Use'AI in the Screen Sector: Perspectives and Paths Forward,' designed to guide the U.K. to 'capitalize on its creative strengths,' mentions the post-production AI use on 'The Brutalist,' among others.
Read more »
Ryan Destiny Fitness Interview and Product RecommendationsRyan Destiny chats with PS about her beginner fitness secrets, including the protein shake she used while training for 'The Fire Inside.'
Read more »
European Behçet's Recommendations ForthcomingWhen to use apremilast and biologics and how to deal with vascular involvement were some of the main areas to be updated in forthcoming EULAR recommendations for Behçet's disease.
Read more »
EULAR, ERS Issue First European Guideline for Managing ILD in Patients With Connective Tissue DiseasesThe guidelines include disease-specific recommendations on screening, monitoring disease progression, and treatment options for ILD.
Read more »